These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 22795080)
1. The practice of urologic oncology: some economic realties. Loughlin KR Urol Oncol; 2012; 30(4 Suppl):S5-9. PubMed ID: 22795080 [TBL] [Abstract][Full Text] [Related]
2. Cost and cost-effectiveness studies in urologic oncology using large administrative databases. Wang Y; Mossanen M; Chang SL Urol Oncol; 2018 Apr; 36(4):213-219. PubMed ID: 29500134 [TBL] [Abstract][Full Text] [Related]
3. The future of urologic cancer care in the United States: our finest hour or a bridge too far. Loughlin KR Urol Oncol; 2010; 28(6):581-4. PubMed ID: 21062646 [No Abstract] [Full Text] [Related]
4. Systemic therapy and the urologic oncologist: a unique opportunity for the specialty to provide comprehensive care that ultimately benefits the patient. Penson DF; Lange PH Urol Oncol; 2012; 30(4 Suppl):S2-4. PubMed ID: 22795076 [TBL] [Abstract][Full Text] [Related]
5. [Active studies of the Working Association for Urological Oncology (AUO) in 2006]. Rexer H Urologe A; 2006 Feb; 45(2):229-40. PubMed ID: 16440204 [No Abstract] [Full Text] [Related]
9. The changing landscape of urologic oncology: initiating systemic therapies, interventional skills, and clinical trials. Introduction. Lin DW; Shore ND Urol Oncol; 2012; 30(4 Suppl):S1. PubMed ID: 22795074 [No Abstract] [Full Text] [Related]
10. Urologic cancer research at the National Cancer Institute. Chiarodo A Semin Urol; 1993 Feb; 11(1):2-6. PubMed ID: 8465123 [No Abstract] [Full Text] [Related]
11. Does urological cancer mortality increase with low population density of physicians? Colli J; Sartor O; Thomas R; Lee BR J Urol; 2011 Dec; 186(6):2342-6. PubMed ID: 22014823 [TBL] [Abstract][Full Text] [Related]
12. New procedures are bound to modify our attitude in facing urologic cancers in the near future: are we ready for a cost-effectiveness analysis? Colombo R Eur Urol; 2007 Jul; 52(1):11-4. PubMed ID: 17399890 [No Abstract] [Full Text] [Related]
14. The future of urologic oncology: "Proceduralists" or continued leaders? Lange PH Urol Oncol; 2009; 27(2):118-9. PubMed ID: 19285218 [No Abstract] [Full Text] [Related]
15. American Society of Clinical Oncology guidance statement: the cost of cancer care. Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE; J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533 [TBL] [Abstract][Full Text] [Related]
17. Oncology in the era of managed care. Gerszten PC J Oncol Manag; 1998; 7(3):21-3. PubMed ID: 10181577 [TBL] [Abstract][Full Text] [Related]
18. Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology Economics Workbook. J Natl Cancer Inst Monogr; 1998; (24):1-28. PubMed ID: 9704318 [No Abstract] [Full Text] [Related]
19. The future of urological oncology: proceduralists or continued primary physicians and leaders. Lange PH J Urol; 2008 Jun; 179(6):2085-6. PubMed ID: 18423757 [No Abstract] [Full Text] [Related]